

# Nasal Polyps - Pipeline Review, H2 2019

<https://marketpublishers.com/r/N39A03302515EN.html>

Date: November 2019

Pages: 102

Price: US\$ 2,000.00 (Single User License)

ID: N39A03302515EN

## Abstracts

Nasal Polyps - Pipeline Review, H2 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasal Polyps - Pipeline Review, H2 2019, provides an overview of the Nasal Polyps (Ear Nose Throat Disorders) pipeline landscape.

Nasal polyps (Nasal polyposis) is an inflammatory condition develops in the nasal lining of nose. They are non-cancerous growths. Signs and symptoms include runny nose, postnasal drip, headache, snoring and loss of sense of taste. Risk factors include asthma, aspirin sensitivity, cystic fibrosis, Churg-strauss syndrome and allergic fungal sinusitis. Treatment includes steroid medications.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasal Polyps - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Nasal Polyps (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasal Polyps (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasal Polyps (Nasal Polyposis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by

Companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 4, 3 and 2 respectively.

Nasal Polyps (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Nasal Polyps (Ear Nose Throat Disorders).

The pipeline guide reviews pipeline therapeutics for Nasal Polyps (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Nasal Polyps (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Nasal Polyps (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Nasal Polyps (Ear Nose Throat Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Nasal Polyps (Ear Nose Throat Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Nasal Polyps (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Nasal Polyps (Nasal Polyposis) - Overview

Nasal Polyps (Nasal Polyposis) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Nasal Polyps (Nasal Polyposis) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nasal Polyps (Nasal Polyposis) - Companies Involved in Therapeutics Development

AnaptysBio Inc

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Idorsia Pharmaceutical Ltd

Kyowa Kirin Co Ltd

Novartis AG

OptiNose US Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Suzhou Connect Biopharmaceuticals Ltd

Nasal Polyps (Nasal Polyposis) - Drug Profiles

ACT-774312 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benralizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBP-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dupilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etokimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fevipirant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluticasone propionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mepolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06817024 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nasal Polyps (Nasal Polyposis) - Dormant Projects

Nasal Polyps (Nasal Polyposis) - Discontinued Products

Nasal Polyps (Nasal Polyposis) - Product Development Milestones

Featured News & Press Releases

Oct 30, 2019: EC approves Dupixent's indication in chronic rhinosinusitis

Sep 20, 2019: Sanofi : CHMP recommends approval of Dupixent (dupilumab) for severe chronic rhinosinusitis with nasal polyposis

Sep 20, 2019: The Lancet publishes results from two positive phase 3 trials of Dupixent (dupilumab) in severe chronic Rhinosinusitis with Nasal Polyps

Sep 12, 2019: Optinose announces \$150 million debt financing from Pharmakon

Jun 27, 2019: FDA approves Regeneron's antibody Dupixent for nasal polyposis

Jun 26, 2019: FDA approves first treatment for chronic rhinosinusitis with nasal polyps

Jun 03, 2019: Xolair (Omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies

May 07, 2019: Dupixent Filed for Sinusitis in Japan: Sanofi

Mar 11, 2019: FDA grants priority review for Sanofi's Dupixent to treat rhinosinusitis

Feb 19, 2019: Optinose announces issuance of four additional U.S. patents covering XHANCE

Feb 15, 2019: Optinose to highlight data at the 2019 AAAAI Annual Meeting in San Francisco

Dec 10, 2018: Optinose announces first patient enrolled in clinical trial of XHANCE for Chronic Sinusitis

Oct 18, 2018: Sanofi's Dupixent meets Phase III trial endpoints for rhinosinusitis

Oct 03, 2018: Optinose to highlight data at two upcoming scientific meetings

Aug 30, 2018: European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1: Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Products under Development by Companies, H2 2019

Table 4: Number of Products by Stage and Target, H2 2019

Table 5: Number of Products by Stage and Mechanism of Action, H2 2019

Table 6: Number of Products by Stage and Route of Administration, H2 2019

Table 7: Number of Products by Stage and Molecule Type, H2 2019

Table 8: Nasal Polyps (Nasal Polyposis) - Pipeline by AnaptysBio Inc, H2 2019

Table 9: Nasal Polyps (Nasal Polyposis) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Table 10: Nasal Polyps (Nasal Polyposis) - Pipeline by GlaxoSmithKline Plc, H2 2019

Table 11: Nasal Polyps (Nasal Polyposis) - Pipeline by Idorsia Pharmaceutical Ltd, H2 2019

Table 12: Nasal Polyps (Nasal Polyposis) - Pipeline by Kyowa Kirin Co Ltd, H2 2019

Table 13: Nasal Polyps (Nasal Polyposis) - Pipeline by Novartis AG, H2 2019

Table 14: Nasal Polyps (Nasal Polyposis) - Pipeline by OptiNose US Inc, H2 2019

Table 15: Nasal Polyps (Nasal Polyposis) - Pipeline by Pfizer Inc, H2 2019

Table 16: Nasal Polyps (Nasal Polyposis) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019

Table 17: Nasal Polyps (Nasal Polyposis) - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, H2 2019

Table 18: Nasal Polyps (Nasal Polyposis) - Dormant Projects, H2 2019

Table 19: Nasal Polyps (Nasal Polyposis) - Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Figure 1: Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products by Targets, H2 2019

Figure 4: Number of Products by Stage and Targets, H2 2019

Figure 5: Number of Products by Mechanism of Actions, H2 2019

Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019

Figure 7: Number of Products by Routes of Administration, H2 2019

Figure 8: Number of Products by Stage and Routes of Administration, H2 2019

Figure 9: Number of Products by Molecule Types, H2 2019

Figure 10: Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

AnaptysBio Inc

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Idorsia Pharmaceutical Ltd

Kyowa Kirin Co Ltd

Novartis AG

OptiNose US Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Suzhou Connect Biopharmaceuticals Ltd



## I would like to order

Product name: Nasal Polyps - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/N39A03302515EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N39A03302515EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970